A Phase I Trial of a Combined Regimen of Chemotherapy and 90Y-Labeled, Humanized LL2 (Anti-CD22) Antibody With Peripheral Stem Cell Rescue for the Treatment of Relapsed or Refractory Non-Hodgkin's Lymphoma.
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 15 Dec 2009
At a glance
- Drugs Epratuzumab Y-90 (Primary) ; Cisplatin; Cytarabine; Etoposide; Ifosfamide
- Indications Chronic lymphocytic leukaemia; Hairy cell leukaemia; Macroglobulinaemia; Non-Hodgkin's lymphoma
- Focus Adverse reactions; Therapeutic Use
- 11 Sep 2005 New trial record.